While medical advances in antiretroviral therapy have reduced HIV’s once fatal implications, rendering it a manageable, chronic condition, a cure has yet to be discovered. The new batch of funds from the NIH comprise the second fiscal implementation of the Martin Delaney Collaboratory: Towards an HIV-1 Cure program and are a part of President Barack Obama’s pledge to invest in HIV cure research. The research initiative is supported by the NIH’s National Institute of Allergy and Infectious Diseases.
“The two greatest challenges remaining in HIV/AIDS research are finding a cure and developing a safe and effective preventive vaccine. This year, NIAID has made significant investments toward both of these critical goals,” said Anthony S. Fauci, MD, director of the NIAID. “A simple, safe and scalable cure for HIV would accelerate progress toward ending the HIV/AIDS pandemic.”
The sites of the research initiatives receiving funds are listed below:
1. George Washington University, Washington, D.C.
2. University of California, San Francisco
3. Fred Hutchinson Cancer Research Center, Seattle
4. Wistar Institute, Philadelphia
5. Beth Israel Deaconess Medical Center, Boston
6. University of North Carolina, Chapel Hill
More articles on infection control:
CDC: Hospitals should not use any liquid docusate for any patient populations due to bacterial outbreak
2 cases of rabbit fever confirmed in New Mexico
Joint Commission adds antimicrobial stewardship standard
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.